Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.
Advertisement

Related Content

Hit By Earthquake and U.S. Restructuring, Shionogi Looks To Regroup In Time For Crestor Loss
GSK Highlights R&D Productivity Gains In First Quarter
Distributing Is Not Licensing: PDL BioPharma Loses Patent, Royalty Battle With MedImmune
R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D
R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D

Topics

Advertisement
UsernamePublicRestriction

Register

PS072166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel